RecruitingPhase 2NCT06245356
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
Studying Dihydropyrimidine dehydrogenase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UNICANCER
- Principal Investigator
- Emmanuelle SAMALIN, MDInstitut du Cancer de Montepllier
- Intervention
- Lonsurf(drug)
- Enrollment
- 73 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (21)
- CHU Amiens, Amiens, France
- Institut de Cancérologie de l'Ouest, Angers, France
- Institut du Cancer d'Avignon, Avignon, France
- CHU Jean Minjoz, Besançon, France
- Centre Hospitalier de Cholet, Cholet, France
- Centre Georges François Leclerc, Dijon, France
- Hôpital Privé Jean Mermoz, Lyon, France
- Institut Régional du Cancer de Montpellier - ICM Val d'Aurelle, Montpellier, France
- Hôpital Saint Louis, Paris, France
- Hôpital Saint Antoine, Paris, France
- Hôpital Cochin, Paris, France
- Hôpital des Diaconesses Croix Saint Simon, Paris, France
- Hospices Civils de Lyon, Pierre-Bénite, France
- CHU de Poitiers, Poitiers, France
- CHU de REIMS, Reims, France
- +6 more locations on ClinicalTrials.gov
Collaborators
Servier
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06245356 on ClinicalTrials.gov